---
title: "Hotgen: The business related to innovative biopharmaceuticals and early cancer screening is operated independently by a joint venture"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247307174.md"
description: "According to the announcement of Hotgen regarding stock price fluctuations, the company's current main business is the research and development, production, and sales of in vitro diagnostic reagents and supporting instruments, as well as biopharmaceuticals and related businesses such as early cancer screening, which are independently operated by the company's joint ventures ShunJing Pharmaceutical, YaoJing Gene, ZhiYuan Bio, and AoRui Bio. These related businesses are characterized by high research and development investment and high research and development risks"
datetime: "2025-07-04T11:51:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247307174.md)
  - [en](https://longbridge.com/en/news/247307174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247307174.md)
generator: "portal-rs"
---

# Hotgen: The business related to innovative biopharmaceuticals and early cancer screening is operated independently by a joint venture

According to the announcement from Zhitong Finance APP, Hotgen (688068.SH) has released a notice regarding stock price fluctuations, stating that the company's current main business is the research and development, production, and sales of in vitro diagnostic reagents and supporting instruments, as well as biopharmaceuticals and related businesses such as early cancer screening, which are independently operated by the company's joint ventures ShunJing Pharmaceutical, YaoJing Gene, ZhiYuan Bio, and AoRui Bio. These related businesses are characterized by high research and development investment and high research and development risks

### Related Stocks

- [688068.CN](https://longbridge.com/en/quote/688068.CN.md)

## Related News & Research

- [Junshi Biosciences Discloses Planned Stake Reduction by Key A-Share Investor](https://longbridge.com/en/news/297448755.md)
- [SEB keeps equity overweight as stronger global growth boosts stock outlook](https://longbridge.com/en/news/297597991.md)
- [Leave a Nest Capital president makes first appearance at TECH GARAGE Seminar in Malaysia](https://longbridge.com/en/news/297597370.md)
- [MEGA: Growth guided at 8%-12% annually, with strong margins and stable 70% dividend payout](https://longbridge.com/en/news/297603854.md)
- [Galle Face Capital Partners publishes annual report for year ended March 31, 2026](https://longbridge.com/en/news/297586883.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**